Largos supervivientes y terapias dirigidas en melanoma avanzado - page 40

1ª línea

•

BRAF

wild-type

• Enfermedad medible

Anti



PD-1

Cobimetinib + Atezolizumab

Pendiente de inicio, fase III

Uso experimental, no autorizado

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1...,30,31,32,33,34,35,36,37,38,39 41,42,43,44,45,46